Conduct of Test Sample Clauses

Conduct of Test. The method of testing established for employees covered by the Omnibus Transportation Employees Testing Act shall also be followed for all employees not covered by said Act.
AutoNDA by SimpleDocs
Conduct of Test. The Acceptance Test will be conducted by the Subscriber, with support from Elsevier, once the agreed services have been completed. The Subscriber will perform the Acceptance Test and report any qualified defects within 14 days upon request from Elsevier. If no qualified defects are reported within this period, the Acceptance Test is considered approved. The requirements for an approved Acceptance Test are fulfilled when the test is conducted without observing one or more qualified defects. A Qualified Defect will mean any one of the following: • the majority of Authorized Users cannot use the Subscribed Software; or • the agreed functionality is reduced to such a degree that the Subscribed Software must be regarded as out of operation; or • the usability of the Subscribed Software is reduced or impeded to a significant extent; or • the usability of the Subscribed Software is reduced to a not inconsiderable extent, unless the defect only affects a few of the relevant users or the defect can be bypassed without a significant extra effort on the part of the Subscriber. It will not be considered a Qualified Defect, if: • only one specific function is not working, unless the function in question is of key significance to the Subscriber's use of the Subscribed Software; or • no more than two (2) Authorized Users out of a larger group of Authorized Users are affected by the defect, and the other Authorized Users in the group can still use the Subscribed Software; or • the failure relates to Subscriber’s use of the Subscribed Products which is not in accordance with the Documentation and/or contrary to Elsevier’s advice. In case the number and content of non-qualified defects are of such an extent that the Subscriber's use of the Subscribed Software is affected thereby as though a Qualified Defect had been present, these will be regarded collectively as a Qualified Defect.
Conduct of Test. Stability: For the one (1) hour prior to the start of and for the duration of the Performance Test, each Unit that is generating shall be operating in steady state mode with all Facility equipment in normal operating service. All non-generating units and plant equipment that affect auxiliary or station power usage shall be operating normally. The Facility, Unit or Units shall meet the stability requirements and stability thresholds established by the applicable ASME Performance Test Code, for the duration of each Test Period. If any stability measurement exceeds code requirements, then the Test Period will be deemed invalid unless otherwise agreed in writing by the parties.
Conduct of Test. Approval criteria.
Conduct of Test. In conducting the testing herein specified, the Employer shall: A. A presumptive test will be conducted at the Ottawa Police Department by the Chief of Police or his designated agent who must be a member of administration. If the test is inconclusive or indicates a positive result, then further testing will be required subject to the paragraph B. B. Use only a clinical laboratory or hospital facility that is licensed pursuant to the Illinois Clinical Laboratory Act, that has or is HHS certified laboratory; C. Provide the employee tested with an opportunity to have additional sample tested by a clinical laboratory or hospital facility (HHS Certified) of the employees own choosing, at the employees own expense. D. Provide each employee tested with a copy of all information and reports received by the employer in connection with the testing and results. E. Ensure that no employee is subject to any adverse employment action except emergency temporary re-assignment or leave with pay during the pendency of any testing procedure. Any such emergency re-assignment or leave shall be immediately discontinued in the event of a negative test result, and all records of the testing procedure will expunge from the employees personnel files; F. Required that the laboratory or hospital facility report to the employer when a blood or urine sample is positive only if both the initial and confirmatory test are positive. The parties agree that should any information concerning such testing, or the results thereof be obtained inconsistent with the understanding expressed herein, the employer and Union shall not use such information in any manner or forum adverse to the employee's interest. Drug testing will be initiated by the Chief of Police or the officer in command in the Chiefs absence. Testing will occur while the employee is on duty except if there is an indication of drug abuse while off duty the officer may be ordered to report for duty immediately and subsequently ordered to submit to testing. Once an officer is ordered to submit to testing the assigned supervisor will remain in continuous visual contact with the officer and the testing will be accomplished with all due haste. Prior to testing a pre-test drug screening form will be completed by the tested officer. This form will indicate any drugs, substances, or medical conditions which might account for a positive drug test. This form will be signed by the officer and supervisor and submitted to the Chief. A urine, bl...

Related to Conduct of Test

  • Conduct of the Study 3.1 Athenex shall act as the sponsor of the Study and shall hold the IND/CTA relating to the Study; provided, however, that in no event shall Athenex file a separate IND/CTA for the Study unless required by Regulatory Authorities to do so. If a Regulatory Authority requests a separate IND/CTA for the Study the Parties will meet and mutually agree on an approach to address such requirement. 3.2 Athenex shall ensure that the Study is performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP. 3.3 Athenex shall ensure that all directions from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are followed. Further, Athenex shall ensure that all Regulatory Approvals from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are obtained prior to initiating performance of the Study. Athenex shall participate in and lead all discussions with any Regulatory Authority regarding the Study, provided, however, that Lilly shall have the right (but no obligation) to participate in any discussions with a Regulatory Authority, and prior review and approval of any written communications with a Regulatory Authorty, regarding matters related to the Lilly Compound. 3.4 Athenex shall maintain reports and all related documentation (paper or electronic versions as applicable) in good scientific manner and in compliance with Applicable Law. Athenex shall provide any Study information and documentation reasonably requested to enable Lilly to (i) comply with any of its legal and regulatory obligations, or any request by any Regulatory Authority, in each case, to the extent related to the Study or such the Lilly Compound, (ii) satisfy any contractual obligation to a subcontractor engaged pursuant to Section 2.4 hereof, and (iii) to determine whether the Study has been performed by Athenex in accordance with this Agreement. 3.5 Athenex shall ensure that all patient authorizations and consents, and all consents from other data subjects, for the processing, use and disclosure of their data and the Clinical Data, required under HIPAA, the EU Data Protection Directive, EU General Data Protection Regulation, and any other similar Applicable Law in connection with the Study, permit the use and sharing of the Clinical Data as set forth in this Agreement, including the sharing of Clinical Data with Lilly. 3.6 All Clinical Data, including raw data and results, generated under this Agreement, as well as the protocol(s), analyses, plans and any other documentation prepared by one or more of the Parties under this Agreement specifically for use in connection with the Study and related to the Lilly Compound, shall be jointly owned by Lilly and Athenex.

  • Conduct of Mediation In consultation with the mediator, the parties will determine a location, timetable and procedure for the mediation or, if the parties cannot agree on these matters within 7 Working Days of the appointment of the mediator these matters will be determined by the mediator.

  • Conduct of Business The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or regulation of any governmental entity, except where such violations would not result, either individually or in the aggregate, in a Material Adverse Effect.

  • Conduct of Hearing The arbitrator shall hold the hearing in Tampa, Florida, unless otherwise agreed by the parties. The hearing shall commence within twenty-five (25) days of the arbitrator's acceptance of selection, or as soon thereafter as is practicable, and the arbitrator shall issue the decision within forty-five (45) days of the close of the hearing or the submission of briefs, whichever is later, unless additional time is agreed to by the parties. The decision shall be in writing and shall set forth findings of fact, reasoning, and conclusions on the issues submitted. Except as expressly specified in this procedure, the provisions of the Florida Arbitration Code, Chapter 682, Florida Statutes, shall not apply. Except as modified by the provisions of the Collective Bargaining Agreement, arbitration proceedings shall be conducted in accordance with the rules and procedures of the American Arbitration Association.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!